doi: 10.1161/hq0901.094247
© 2001 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Paraoxonase Status in Coronary Heart Disease
Are Activity and Concentration More Important Than Genotype?
From the University Department of Medicine (B.M., P.N.D., M.I.M.) and the Department of Cardiology (W.T.), Manchester Royal Infirmary, and the Biostatistics Group (E.H., C.R.), School of Epidemiology and Health Sciences, University of Manchester, Manchester, UK, and the Department of Cardiology (G.K.D., E.L., D.H.R.), Royal Victoria Hospital, Blackpool, UK.
Correspondence to Dr Bharti Mackness, University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL UK. E-mail bmack{at}central.cmht.nwest.nhs.uk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—— Human serum paraoxonase (PON1) hydrolyzes oxidized lipids in low density lipoprotein (LDL) and could therefore retard the development of atherosclerosis. In keeping with this hypothesis, several case-control studies have shown a relationship between the presence of coronary heart disease (CHD) and polymorphisms at amino acid positions 55 and 192 of PON1, which we associated with a decreased capacity of PON1 to protect LDL against the accumulation of lipid peroxides, but some other studies have not. However, the PON1 polymorphisms are only 1 factor in determining the activity and concentration of the enzyme. Only 3 of the previous 18 studies directly determined PON1 activity and concentration. Therefore, we studied PON1 activity, concentration, and gene distribution in 417 subjects with angiographically proven CHD and in 282 control subjects. We found that PON1 activity and concentration were significantly lower in subjects with CHD than in control subjects (activity to paraoxon 122.8 [3.3 to 802.8] versus 214.6 [26.3 to 620.8] nmol · min-1 · mL-1, P<0.001; concentration 71.6 [11.4 to 489.3] versus 89.1 [16.8 to 527.4] µg/mL, P<0.001). There were no differences in the PON1-55 and -192 polymorphisms or clusterin concentration between patients with CHD and control subjects. These results indicate that lower PON1 activity and concentration and, therefore, the reduced ability to prevent LDL lipid peroxidation may be more important in determining the presence of CHD than paraoxonase genetic polymorphisms.
Key Words: paraoxonase • oxidation • coronary heart disease • genetic polymorphisms
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Paraoxonase (EC.3.1.8.1, aryldialkylphosphatase) has been extensively studied in the field of toxicology.1,2 Paraoxonase hydrolyzes organophosphate compounds, which are widely used as insecticides and nerve gases.3,4 Human serum paraoxonase (PON1) is synthesized in the liver and is physically associated with HDL, on which it is almost exclusively located. The serum concentration of HDL has long been known to have an inverse correlation with the development of atherosclerosis.5 The mechanism by which HDL renders its protective effect against atherosclerosis continues to be the subject of considerable debate. The initial focus of attention was on the role of HDL in reverse-cholesterol transport. However, recent studies have suggested more diversity in the role of HDL in atherogenesis. Several laboratories have reported that HDL protects against LDL oxidative modification,6–9 which is believed to be central to the initiation and progression of atherosclerosis.10 We have previously shown that the antioxidant activity of HDL may relate, at least in part, to the enzymes associated with HDL.11 Further studies have indicated that PON1 can prevent lipid peroxide accumulation on LDL in vitro and in vivo.12–14 Studies have shown that serum PON1 activity is reduced in diabetes and familial hypercholesterolemia,15,16 diseases that are associated with accelerated atherogenesis.
PON1 activity is in part genetically determined. In this regard, most investigations have focused on an amino acid substitution at position 192 (Q
R), giving rise to 2 allozymes.3,17,18 This PON1 activity polymorphism is substrate dependent. Some substrates, such as paraoxon and fenitroxon, are hydrolyzed faster by the R allozyme, whereas other substrates, such as phenyl acetate, are hydrolyzed at the same rate by both allozymes, and yet others, such as diazoxon and the nerve gases soman and sarin, are hydrolyzed more rapidly by the Q allozyme.19 A second polymorphism of the PON1 gene is present at the amino acid at position 55 (LM). This polymorphism has also been shown to have an effect on PON1 activity. Although this is much smaller than that of the 192 polymorphism,20,21 it is independent of the 192 polymorphism.
We have recently shown that the PON1 R allozyme is less efficient at retarding the oxidation of LDL than is the Q allozyme because of the decreased hydrolysis of lipid peroxides by the R allozyme.22,23 This has been confirmed by other workers24 and indicates that the efficacy of the 2 allozymes toward lipid peroxides is opposite that toward paraoxon, the substrate most commonly used to assay PON1 activity.22–24 These findings may explain why in some case-control studies the paraoxonase R allele has been found to be present at an increased frequency in coronary heart disease (CHD),25–32 leading to the hypothesis that the PON1-192 polymorphism might be a risk factor for atherosclerosis. However, some studies have failed to find such a relationship,32–41 but in none has the R allele been less common than in patients with CHD (see Discussion). Unfortunately, the majority of these studies were exclusively genetic, with no measurements of PON1 activity or mass. Only 3 of the 18 previous studies directly measured PON1 activity or mass.25,30,41
The Fogelman group (Watson et al14) has reported that PON1 in HDL may block inflammatory responses by preventing the oxidation of LDL. The same group went on to demonstrate that during an acute-phase reaction, there is a significant loss of the PON1 activity, thus accounting for the failure of HDL to protect LDL from oxidation during acute-phase reactions.42 More recently, the Fogelman group (Navab et al43) reported a failure of HDL to protect LDL from oxidation in patients with coronary atherosclerosis, which they proposed was due to their low serum PON1 activity. We found a decrease in serum PON1 activity and concentration in myocardial infarction within 2 hours of the onset of symptoms; PON1 did not change up to 42 days after the myocardial infarction, long after the acute phase had passed, strongly suggesting that a decrease in its activity may have preceded the acute event.44 The decrease was substantially greater than could be accounted for by any differences in the prevalence of PON1 polymorphisms between patients developing CHD and control subjects.
Therefore, we hypothesized that in CHD the status of PON1 (ie, its activity and concentration) would be more important than the PON1 genotype. It has been suggested that an increased ratio of apoJ to PON1 may be a better indicator of atherosclerosis than the ratio of total cholesterol to HDL cholesterol (HDL-C).43 To test these hypotheses, we analyzed these parameters and apoJ in a population of >400 people with angiographically proven CHD and a population without CHD.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
Patients included in the present study were all outpatients attending the Cardiology Departments at either Manchester Royal Infirmary, UK, or the Royal Victoria Hospital, Blackpool, UK. All patients had angiographically proven CHD, which was visually assessed. All patients had stenosis that was severe enough to require intervention either by coronary angioplasty or surgery. No patient had sustained a myocardial infarction within 6 months before taking part in the study. Patients with diabetes or renal or hepatic disease were excluded from the study. Four hundred seventeen sequential patients who fulfilled the inclusion criteria were studied. Fully informed consent was obtained, and the study was approved by the Central Manchester Healthcare NHS Trust Research Ethical Committee. One hundred four patients were receiving a ß-adrenoceptor-blocking drug, 89 were taking a calcium channel blocker, and 154 were on lipid-lowering medication (151 received statins, and 3 received fibrates). All patients were receiving aspirin (75 or 150 mg daily).
The control population consisted of 282 (147 men) healthy subjects, who either attended a routine health check at a general practice or at their place of work. Lack of coronary artery disease in the control population was assessed by use of a health questionnaire, and all had no history suggestive of coronary artery disease. Subjects with diabetes or renal or hepatic disease were excluded. The demographic details of the patients and controls are given in Table 1.
|
Venous blood was collected from all subjects between 9:00 and 11:00 AM after fasting from 10:00 PM the previous day. Serum and plasma were isolated by low-speed centrifugation. White cells were removed from the buffy coat of the plasma tube. HDL was isolated immediately by precipitating LDLs with heparin-Mn2+. Other samples were stored at -20°C for no more than 2 months before analysis.
Serum Lipids
Serum cholesterol and HDL-C were determined by the CHOD-PAP method (Cobas Mira, Roche). Serum triglycerides were measured by the enzymatic GPO-PAP method (Cobas Mira, Roche). ApoA-I and apoB were determined by immunoturbidimetry on the Cobas Mira by using reagents, standards, and controls provided by the manufacturer. LDL cholesterol was estimated by the Friedewald formula:
LDL cholesterol = total serum cholesterol-(HDL cholesterol + triglyceride/2.2) mmol/L
Analysis of PON1 Activity
PON1 activity was measured by adding serum to Tris buffer (100 mmol/L, pH 8.0) containing 2 mmol/L CaCl2 and 5.5 mmol/L paraoxon (O,O-diethyl-O-p-nitrophenylphosphate, Sigma Chemical Co). The rate of generation of p-nitrophenol was determined at 405 nm, 25°C, with the use of a continuously recording spectrophotometer (Beckman DU-68) as described previously.15
Determination of PON1 Concentration
PON1 concentration was determined by using our in-house competitive ELISA with rabbit anti-human PON1 monospecific antibodies used as described previously.16
Determination of PON1 Genotype
DNA was extracted from the white cells, and PON1 genotype for the 192 and 55 polymorphisms was determined by polymerase chain reaction amplification and restriction enzyme digestion as described.17,18
Determination of ApoJ (Clusterin) Concentration
ApoJ concentration was determined by ELISA with monoclonal antibodies to human clusterin and pure clusterin used as standards (both were purchased from Quidel) as described previously.43 Interassay and intra-assay coefficients of variation were 7.2% and 4.2%, respectively.
Statistical Analysis
The Wilcoxon signed rank test was used to test for differences in variables with a nongaussian frequency distribution, namely, PON1 activity toward paraoxon and PON1 concentration and triglyceride concentration. The Student unpaired t test was used for total cholesterol, LDL, HDL, apoA-I, and apoB estimations. A value of P<0.05 was considered statistically significant. The Spearman correlation coefficient was used to test the strength of any associations between different variables. Differences in gene frequency were sought by the 
2 test. ANOVA was used to test for differences in parameters between genotypes.
A meta-analysis of previously published studies was carried out to examine the relationship between the PON1 R allele and CHD by estimating a pooled odds ratio by first comparing alleles per genotype RR and QR against QQ and then alleles RR against QR and QQ. In meta-analyses, it is important to examine whether there is heterogeneity of effect between studies. When there is a random effect rather than a fixed effect, meta-analysis is considered more appropriate.45 It is also important to examine the relationship between study effect and sample size. When there is evidence of a large effect in studies with a smaller sample size, this may indicate publication bias46 that is due to the lack of publication of smaller nonsignificant studies. Metaregression techniques were used to examine any difference associated with race.47 Statistical analysis was carried out by using the Stata Statistical Software Package (StataCorp 1999, Stata Statistical Software, Release 6).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Compared with the control group, the study population had a greater proportion of males, was significantly older, and had a larger average body mass index (Table 1). The CHD group also had significantly higher serum triglyceride levels and lower total cholesterol and apoA-I levels than did the control group. However, there were no differences in HDL-C or apoB between the groups (Table 1).
There were no significant differences between the populations in the gene frequencies of either PON1-55 or PON1-192. Genotype frequencies for the Q192R polymorphism were 55.3% QQ, 35.1% QR, and 8.5% RR (Q=0.74, R=0.26) in the control subjects and 50.1% QQ, 41.5% QR, and 7.7% RR (Q=0.71, R=0.29) in the CHD population. Genotype frequencies for the L55M polymorphism were 36.9% LL, 52.8% LM, and 9.2% MM in the control subjects (L=0.64, M=0.36) and 40.3% LL, 47.7% LM, and 11.3% MM (L=0.65, M=0.35) in the CHD population. However, paraoxon hydrolysis was 50% less in the CHD population than in the control group (P<0.001). PON1 concentration was also significantly reduced (Table 2). The serum clusterin concentration was the same in the 2 populations. The apoA-I/PON1 and HDL-C/PON1 ratios were both higher in the CHD population. The difference in PON1 activity between the control and CHD populations was tested for independence from other variables by multiple regression analysis. The model included sex, age, body mass index, total cholesterol, triglycerides, HDL, apoB, apoA-I, clusterin, PON1 concentration, and the PON1-55 and -192 polymorphisms (Table 3). The difference in PON1 activity was found to be dependent on differences in age (P=0.047), total cholesterol (P=0.049), apoA-I (P=0.025), and PON1 concentration (P=0.0031)
|
|
Total cholesterol was lower in those CHD subjects taking statins than in those not taking statins (4.7±1.1 versus 5.2±0.9, respectively; P<0.01), and HDL-C was significantly higher (1.55±0.42 versus 1.46±0.50, respectively; P<0.05). However, there were no significant differences in triglycerides, apoA-I, apoB, paraoxon hydrolysis, PON1 concentration, or clusterin between those taking statins and those not taking statins (result not shown). The reason(s) for the different responses of apoA-I and apoB to total cholesterol and HDL-C is unclear but is probably due to the mode of action of statin drugs.
The effect of the PON1-55 and -192 polymorphisms on paraoxon hydrolysis was similar to that reported in previous studies from our laboratory.21,48 Thus, paraoxon hydrolysis was lowest in MM/QQ individuals and highest in the LL/RR genotype (Table 4). There was no effect of genotype on PON1 concentration (Table 4). PON1 activities toward paraoxon and concentration were lower in the CHD population regardless of genotype (Table 4). PON1 specific activity was significantly lower in the QQ/MM genotypes in the control and CHD populations and in the QR/MM genotype in the control population than in other genotypes (Table 4). Overall PON1 specific activity was lower in the CHD population than in the control group (Tables 3 and 4).
|
The Figure illustrates the studies identified from a systematic search of the literature. When the risk of CHD for RR and QR alleles was compared with that for the QQ allele, there was evidence of heterogeneity of odds between studies (P<0.001); ie, studies have different odds ratios. A random-effect meta-analysis, appropriate when there is heterogeneity between studies, gave a pooled odds ratio of 1.44 (95% CI 1.17 to 1.77), which is significantly different from 1.0 (P=0.001). There was no evidence of any race effect (P=0.53). In a test comparing study effect size with sample size, there was some evidence of a large effect in small studies (P=0.008). This can be seen in the top panel of the Figure; smaller studies having a smaller mark (presented as a square) and wider CI tend to show a larger effect. This suggests that smaller nonsignificant studies may have been missed because of a lack of publication or publication in more obscure journals, which could have been missed from our search, sometimes referred to as publication bias.
|
When allele RR was compared with alleles QR and QQ, the results were similar but less strong. There was again evidence of heterogeneity of the odds ratio between studies (P=0.065). In a random effect meta-analysis, the pooled estimate of the odds ratio was 1.162 (95% CI 1.00 to 1.35), which is just significantly different from 1 at conventional levels (P=0.05). There was again no evidence of a race effect (P=0.237), and there was some suggestion of publication bias (P=0.103).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Previous studies that have investigated the relationship between the PON1-192 genetic polymorphism and CHD have produced inconsistent results. Some studies have shown the PON1-192R genotype to be present at a higher frequency in CHD, leading to the hypothesis that the PON1-192 polymorphism might be a risk factor for atherosclerosis,25–32 but some studies have failed to find such a relationship.32–41 However, no study has found the R allele to be less common in CHD. We have carried out a meta-analysis on all studies published (at the time of writing this article) on the PON1-192 genotype in CHD and found that overall there is an increase in the frequency of the PON1-192R allele in CHD (Figure). Given the suggestion of publication bias, ie, evidence of a large effect in smaller studies, which is possibly due to the lack of publication of studies with a small nonsignificant effect, any conclusion must be treated with caution. There was also evidence of heterogeneity between studies. To summarize the meta-analysis, there was evidence that the R allele was associated with increased risk of CHD. There was no evidence of a difference associated with race. Far fewer studies have been conducted into the relationship between the PON1-55 polymorphism with CHD, but again, inconsistent results have been produced.49 However, the vast majority of the studies described above did not measure the quality of PON1, ie, its activity and mass in the serum of the individuals studied, which in the present study were lower in the CHD population than in the control subjects regardless of PON1 genotype. The lack of data on PON1 activity and concentration may well have been a cause of the variation in the studies that was due to a normal PON1 activity/mass in those studies showing no relationship between PON1 polymorphisms and CHD. Differences in PON1 activity and concentration between populations of the same ethnic group are well known,50,51 which, if not taken into account, could have affected the results of the case-control studies. In addition, proatherogenic diets have been shown to reduce PON1 in mice, rabbits, and humans.52–54 Lipid peroxides, which are substrates for PON1 and which have been shown to be raised in people with CHD,55 are inhibitors of PON1.56 Thus, acquired factors that are prevalent in CHD may be responsible for the lower PON1 found in CHD rather than genetic factors. However, genetic factors other than the 55 and 192 polymorphisms should not be entirely dismissed. Recent evidence has indicated that polymorphisms in the promoter region of the PON1 gene are important in determining levels of PON1,57 and a low expressor promoter polymorphism has been associated with increased CHD in a diabetic population.58 Whether the promoter polymorphism determining low PON1 is more prevalent in nondiabetic CHD has yet to be established.
As we have shown, however, it is likely that PON1 activity and mass are more important determinants of susceptibility to CHD than are the PON1-55 and PON1-192 genotypes. In a previous study, we showed that PON1 activity and concentration were significantly reduced within 2 hours of the onset of myocardial infarction. PON1 did not change up to 42 days after the myocardial infarction, long after the acute phase had passed, strongly suggesting that it was lower before the event.44 In the present study, we have shown that PON1 activity and mass are reduced independently of the PON1 genotype in people with established CHD. Interestingly, a recent, although smaller, study, reached the same conclusion, finding the measurement of PON1 activity to be a better prediction of carotid artery disease than either the PON1-55 or PON1-192 genotype.59 Low or absent PON1 has been associated with an inability of HDL to prevent the oxidation of LDL in humans and in animal models.43,60–62 Low PON1 has been shown to reduce the capacity of HDL to prevent the oxidation of LDL63,64 and may, therefore, lead to CHD.
The results of an earlier study have suggested that the ratio of clusterin to PON1 may be a more accurate predictor of CHD than the ratio of total cholesterol to HDL-C.43 However, in the present investigation, we found no differences in the serum clusterin concentration between the CHD and control populations. The reason for this difference between to 2 studies is unclear but could be due to sample size, which was very low in the previously reported study.43 In the present study, the ratio of PON1 to either clusterin, apoA-I, or HDL-C appears largely to reflect the low PON1 in the CHD population.
In summary, we have shown that PON1 activities toward paraoxon and PON1 concentrations are lower in subjects with CHD than in control subjects regardless of the PON1 genotype. This would suggest that the quality of the PON1 enzyme is a more important factor in CHD than is the PON1 gene. At the present time, the effect of the deranged enzyme activity appears to be substrate dependent, and further studies investigating the hydrolysis of lipid peroxides by PON1 in CHD are warranted. We, along with other authors,59,65 would strongly suggest that all further epidemiological studies into the role of PON1 and disease should include a measurement of the enzyme itself in addition to the genetic polymorphisms. In the absence of a routine assay based on the hydrolysis of lipid peroxides, this measurement should include either the hydrolysis of paraoxon and/or diazoxon or the concentration of the enzyme.
|
Acknowledgments |
|---|
The authors would like to thank Caroline Price for expert typing of the manuscript and S. Arrol, M. Hall, and S. Middleton for technical assistance.
Received November 10, 2000; accepted May 17, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Aldridge WN. Serum esterase I: two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate and a method for their determination. Biochem J. . 1953; 53: 110–117.[Medline] [Order article via Infotrieve]
2. Aldridge WN. Serum esterase II: an enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J. . 1953; 53: 117–124.[Medline] [Order article via Infotrieve]
3. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York, NY: Pergamon Press; 1992: 51–91.
4. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol. . 1996; 7: 69–76.[Medline] [Order article via Infotrieve]
5. Gordon D. In: Durrington PN, ed. HDL: where should the clinician stand? UK: Mark Allen Publishing; 1992: 17–20.
6. Klimov AN, Kozhemyakin LA, Pleskov VM, Andreeva LI. Antioxidative effect of high density lipoproteins in the oxidation of low density lipoproteins [in Russian]. Biull Eksp Biol Med. . 1987; 103: 550–556.[Medline] [Order article via Infotrieve]
7. Mackness MI, Abbott CA, Arrol S, Durrington PN. The role of high density lipoprotein and lipid soluble antioxidant vitamins in inhibiting low density lipoprotein oxidation. Biochem J. . 1993; 294: 829–834.
8. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. . 1990; 1044: 275–283.[Medline] [Order article via Infotrieve]
9. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H. et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. . 1991; 88: 2039–2046.
10. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. . 1989; 320: 915–924.[Medline] [Order article via Infotrieve]
11. Mackness MI, Durrington PN. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. . 1995; 115: 243–253.[Medline] [Order article via Infotrieve]
12. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. . 1991; 286: 152–154.[Medline] [Order article via Infotrieve]
13. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. . 1993; 104: 129–135.[Medline] [Order article via Infotrieve]
14. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest. . 1995; 96: 2882–2891.
15. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. . 1991; 86: 193–198.[Medline] [Order article via Infotrieve]
16.
Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. . 1995; 15: 1812–1818.
17. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. . 1993; 52: 598–608.[Medline] [Order article via Infotrieve]
18. Humbert R, Adler DA, Disteche CK, Hassett C, Omiecinski CJ, Furlong EC. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. . 1993; 3: 73–76.[Medline] [Order article via Infotrieve]
19. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. . 1996; 14: 334–336.[Medline] [Order article via Infotrieve]
20. Blatter Garin, M-C., James RW, Dussoix P, Blanche H, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified concentrations of the enzyme. J Clin Invest. . 1997; 99: 62–66.[Medline] [Order article via Infotrieve]
21. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. . 1997; 112: 265–268.
22. Mackness MI, Arrol S, Mackness B, Durrington PN. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet. . 1997; 349: 851–852.[Medline] [Order article via Infotrieve]
23. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. . 1998; 423: 57–60.[Medline] [Order article via Infotrieve]
24. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du BN. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective active of human paraoxonase alloenzymes Q and R. Arterioscler Thromb Vasc Biol. . 1998; 10: 1617–1624.
25. Ruiz J, Blanche H, James RW, Garin, M-CB, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. . 1995; 346: 869–872.[Medline] [Order article via Infotrieve]
26. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. . 1995; 96: 3005–3008.
27.
Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. . 1997; 82: 2257–2260.
28.
Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y. A 192-Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol. . 1997; 17: 3565–3569.
29. Pfohl M, Koch M, Euderle MD, Kühn R, Füllhase J, Karsch KR, Haring HU. Paraoxonase 192 Glu/Arg Gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. . 1999; 48: 623–627.[Abstract]
30. Pati N, Pati U. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int J Cardiol. . 1998; 66: 165–168.[Medline] [Order article via Infotrieve]
31. Imai Y, Marita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis. . 2000; 149: 435–442.[Medline] [Order article via Infotrieve]
32.
Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. . 1997; 17: 1067–1073.
33. Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C. The Gln-Arg 191 polymorphism of human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest. . 1996; 98: 883–885.[Medline] [Order article via Infotrieve]
34. Aubó C, Sentí M, Marragut J, Tomá M, Vila J, Sala J, Masiá R. Risk of myocardial infarction with Gln/Arg 192 polymorphisms in the human paraoxonase gene and diabetes mellitus. Eur Heart J. . 2000; 21: 31–38.
35. Cascorbi I, Laule M, Mrozikiewicz PM, Mrozikiewicz A, Andel C, Baumann G, Roots I, Stangl K. Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages and association with coronary artery disease. Pharmacogenetics. . 1999; 9: 755–761.[Medline] [Order article via Infotrieve]
36. Herrmann SM, Blanc H, Poirier O, Arveiter D, Luc G, Evans A, Marques-Vidal P, Bard JM, Cambien F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. . 1996; 126: 299–304.[Medline] [Order article via Infotrieve]
37.
Ombres D, Pannitteri G, Moutali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Arca M. The Gln-Arg 192 polymorphism of the human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol. . 1998; 18: 1611–1616.
38. Rice GI, Ossei-Geoning N, Stickland MH, Grant PJ. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron Artery Dis. . 1997; 8: 677–682.[Medline] [Order article via Infotrieve]
39. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, Hashimoto K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol. . 1996; 57: 69–73.[Medline] [Order article via Infotrieve]
40. Ko Y-L, Ko Y-S, Wang S-M, Hsu L-A, Chang C-J, Chu P-H, Cheng NJ, Chen WJ, Chiang CW, Lee YS. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis. . 1998; 141: 259–264.[Medline] [Order article via Infotrieve]
41. Hasselwander O, Savage DA, McMaster D, Loughrey CM, McNamee PT, Middleton D, Nicholls DP, Maxwell AP, Young IS. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int. . 1999; 56: 289–298.[Medline] [Order article via Infotrieve]
42. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest. . 1995; 96: 2758–2767.
43. Navab M, Hama SY, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Lusis LJ, Fogelman AM. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. . 1997; 99: 2005–20.[Medline] [Order article via Infotrieve]
44.
Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. . 1999; 19: 330–335.
45. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. . 1986; 7: 177–188.[Medline] [Order article via Infotrieve]
46.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. . 1997; 315: 629–634.
47. Lau J, Ionanides PA, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. . 1998; 351: 123–127.[Medline] [Order article via Infotrieve]
48. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuashia B, Miller JE, Boulton AJM, Durrington PN. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. . 1998; 139: 341–349.[Medline] [Order article via Infotrieve]
49. Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol. . 2000; 11: 383–3887.[Medline] [Order article via Infotrieve]
50. Blatter Garin M-C, Abbott C, Messmer S, Mackness MI, Durrington PN, Pometta D, James RW. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. . 1994; 304: 549–554.
51. Mackness B, Mackness MI, Durrington PN, Arrol S, Evans AE, McMaster D, Ferrières J, Ruidavets J-B, Williams NR, Howard AN. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest. . 2000; 30: 4–10.[Medline] [Order article via Infotrieve]
52. Shih DM, Gu L, Hama S, Xia Y-R, Navab M, Fogelman AM, Lusis AJ. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. . 1996; 97: 1630–1639.[Medline] [Order article via Infotrieve]
53. Mackness M, Bouiller A, Hennuyer N, Mackness B, Hall M, Tailleux A, Duriez P, Delfly B, Durrington PN, Fruchart J-C, et al. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun. . 2000; 269: 232–236.[Medline] [Order article via Infotrieve]
54.
Sutherland WHF, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol. . 1999; 19: 1340–1347.
55. Liu K, Cuddy TE, Pierce GN. Oxidative status of lipoproteins in coronary disease patients. Am Heart J. . 1992; 123: 285–289.[Medline] [Order article via Infotrieve]
56. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B. Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. . 1999; 26: 892–904.[Medline] [Order article via Infotrieve]
57.
Leviev I, James RW. Promoter polymorphisms of the human paraoxonase PON1 gene and serum activities and concentrations. Arterioscler Thromb Vasc Biol. . 2000; 20: 516–521.
58. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Blatter Garin M-C. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes. . 2000; 49: 1390–1393.[Abstract]
59.
Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol. . 2000; 20: 2441–2447.
60. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. . 1998; 394: 284–287.[Medline] [Order article via Infotrieve]
61. Mackness B, Durrington PN, Mackness MI. Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Commun. . 1998; 247: 443–446.[Medline] [Order article via Infotrieve]
62. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today. . 1999; 5: 381–386.[Medline] [Order article via Infotrieve]
63.
Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. . 2000; 41: 1481–1494.
64.
Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. . 2000; 41: 1495–1508.
65. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. . 1999; 9: 745–753.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. GLUBA, M. BANACH, D. P. MIKHAILIDIS, and J. RYSZ Genetic Determinants of Cardiovascular Disease: The Renin-Angiotensin-Aldosterone System, Paraoxonases, Endothelin-1, Nitric Oxide Synthase and Adrenergic Receptors In Vivo, September 1, 2009; 23(5): 797 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Richter, G. P. Jarvik, and C. E. Furlong Determination of Paraoxonase 1 Status Without the Use of Toxic Organophosphate Substrates Circ Cardiovasc Genet, December 1, 2008; 1(2): 147 - 152. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Movva and D. J. Rader Laboratory Assessment of HDL Heterogeneity and Function Clin. Chem., May 1, 2008; 54(5): 788 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Thyagarajan, D. R. Jacobs Jr., J. J. Carr, O. Alozie, M. W. Steffes, P. Kailash, J. H. Hayes, and M. D. Gross Factors Associated with Paraoxonase Genotypes and Activity in a Diverse, Young, Healthy Population: The Coronary Artery Risk Development in Young Adults (CARDIA) Study Clin. Chem., April 1, 2008; 54(4): 738 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bhattacharyya, S. J. Nicholls, E. J. Topol, R. Zhang, X. Yang, D. Schmitt, X. Fu, M. Shao, D. M. Brennan, S. G. Ellis, et al. Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular Risk JAMA, March 19, 2008; 299(11): 1265 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Connelly, G. F. Maguire, C. M. Picardo, J. F. Teiber, and D. Draganov Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma J. Lipid Res., January 1, 2008; 49(1): 245 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sarandol, S. Kirli, C. Akkaya, N. Ocak, E. Eroz, and E. Sarandol Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment J Psychopharmacol, November 1, 2007; 21(8): 857 - 863. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Deakin, X. Moren, and R. W. James HDL Oxidation Compromises its Influence on Paraoxonase-1 Secretion and its Capacity to Modulate Enzyme Activity Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1146 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Browne, S. T. Koury, S. Marion, G. Wilding, P. Muti, and M. Trevisan Accuracy and Biological Variation of Human Serum Paraoxonase 1 Activity and Polymorphism (Q192R) by Kinetic Enzyme Assay Clin. Chem., February 1, 2007; 53(2): 310 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Ng, N. Bourquard, V. Grijalva, S. Hama, D. M. Shih, M. Navab, A. M. Fogelman, A. J. Lusis, S. Young, and S. T. Reddy Paraoxonase-2 Deficiency Aggravates Atherosclerosis in Mice Despite Lower Apolipoprotein-B-containing Lipoproteins: ANTI-ATHEROGENIC ROLE FOR PARAOXONASE-2 J. Biol. Chem., October 6, 2006; 281(40): 29491 - 29500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Graner, R. W. James, J. Kahri, M. S. Nieminen, M. Syvanne, and M.-R. Taskinen Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2429 - 2435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Marchegiani, M. Marra, L. Spazzafumo, R. W. James, M. Boemi, F. Olivieri, M. Cardelli, L. Cavallone, A. R. Bonfigli, and C. Franceschi Paraoxonase activity and genotype predispose to successful aging. J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 541 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Blatter Garin, X. Moren, and R. W. James Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I J. Lipid Res., March 1, 2006; 47(3): 515 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Shih, H. R. Kast-Woelbern, J. Wong, Y.-R. Xia, P. A. Edwards, and A. J. Lusis A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids J. Lipid Res., February 1, 2006; 47(2): 384 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gutierrez, E. P. Ratliff, A. M. Andres, X. Huang, W. L. McKeehan, and R. A. Davis Bile Acids Decrease Hepatic Paraoxonase 1 Expression and Plasma High-Density Lipoprotein Levels Via FXR-Mediated Signaling of FGFR4 Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 301 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Erlich, K. L. Lunetta, L. A. Cupples, M. Huyck, R. C. Green, C. T. Baldwin, L. A. Farrer, and for the MIRAGE Study Group Polymorphisms in the PON gene cluster are associated with Alzheimer disease Hum. Mol. Genet., January 1, 2006; 15(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bradshaw, A. Gutierrez, J. H. Miyake, K. R. Davis, A. C. Li, C. K. Glass, L. K. Curtiss, and R. A. Davis Facilitated replacement of Kupffer cells expressing a paraoxonase-1 transgene is essential for ameliorating atherosclerosis in mice PNAS, August 2, 2005; 102(31): 11029 - 11034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J. Lipid Res., March 1, 2005; 46(3): 389 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Madamanchi, A. Vendrov, and M. S. Runge Oxidative Stress and Vascular Disease Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 29 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nguyen and D.-E. Sok Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids J. Lipid Res., December 1, 2004; 45(12): 2211 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Voetsch and J. Loscalzo Genetic Determinants of Arterial Thrombosis Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 216 - 229. [Abstract] [Full Text]
|
|
|
|
|
|
G. P. Jarvik, T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1465 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mackness, P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study Circulation, June 10, 2003; 107(22): 2775 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Cabana, C. A. Reardon, N. Feng, S. Neath, J. Lukens, and G. S. Getz Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response J. Lipid Res., April 1, 2003; 44(4): 780 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gouedard, N. Koum-Besson, R. Barouki, and Y. Morel Opposite Regulation of the Human Paraoxonase-1 Gene PON-1 by Fenofibrate and Statins Mol. Pharmacol., April 1, 2003; 63(4): 945 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rosenblat, D. Draganov, C. E. Watson, C. L. Bisgaier, B. N. La Du, and M. Aviram Mouse Macrophage Paraoxonase 2 Activity Is Increased Whereas Cellular Paraoxonase 3 Activity Is Decreased Under Oxidative Stress Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 468 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, Z. Fan, J. Huang, S. Su, Q. Yu, J. Zhao, R. Hui, Z. Yao, Y. Shen, B. Qiang, et al. Extensive Association Analysis Between Polymorphisms of PON Gene Cluster With Coronary Heart Disease in Chinese Han Population Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 328 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.N. Durrington, B. Mackness, and M.I. Mackness The Hunt for Nutritional and Pharmacological Modulators of Paraoxonase Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1248 - 1250. [Full Text] [PDF]
|
|
|
|
|
|
G. P. Jarvik, N. T. Tsai, L. A. McKinstry, R. Wani, V. H. Brophy, R. J. Richter, G. D. Schellenberg, P. J. Heagerty, T. S. Hatsukami, and C. E. Furlong Vitamin C and E Intake Is Associated With Increased Paraoxonase Activity Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1329 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Voetsch, K. S. Benke, B. P. Damasceno, L. H. Siqueira, and J. Loscalzo Paraoxonase 192 Gln->Arg Polymorphism: An Independent Risk Factor for Nonfatal Arterial Ischemic Stroke Among Young Adults Stroke, June 1, 2002; 33(6): 1459 - 1464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Levinson High Density- and Beta-Lipoprotein Screening for Risk of Coronary Artery Disease in the Context of New Findings on Reverse Cholesterol Transport Ann. Clin. Lab. Sci., April 1, 2002; 32(2): 123 - 136. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||